n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with Dry Eye in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bar-Yehuda, S; Cohen, S; Fishman, P | 1 |
| Avni, I; Bakshi, E; Barequet, IS; Bristol, DR; Chetrit, N; Cohn, I; Farbstein, M; Fishman, P; Fishman, S; Garzozi, HJ; Harpaz, Z; Jacobson, KA; Kerns, WD; Litvin, G; Sartani, G; Segev, F; Silverman, MH; Tomkins, O; Varssano, D; Yehuda, SB; Zadok, D | 1 |
| Ashar, JN; Mathur, A; Sangwan, V | 1 |
1 review(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Dry Eye
| Article | Year |
|---|---|
Targeting the A3 adenosine receptor for glaucoma treatment (review).
Topics: Adenosine; Adenosine A3 Receptor Agonists; Anti-Inflammatory Agents; Apoptosis; Dry Eye Syndromes; Glaucoma; Humans; Intraocular Pressure; Receptor, Adenosine A3; Retinal Ganglion Cells | 2013 |
1 trial(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Dry Eye
| Article | Year |
|---|---|
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Administration, Oral; Cornea; Double-Blind Method; Dry Eye Syndromes; Electrocardiography; Female; Fluorophotometry; Humans; Intraocular Pressure; Male; Middle Aged; Tears; Treatment Outcome | 2010 |
1 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Dry Eye
| Article | Year |
|---|---|
CF101 for dry eye.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Administration, Oral; Cornea; Dry Eye Syndromes; Humans; Tears; Treatment Outcome | 2011 |